Related Experiment Video
Updated: Jan 8, 2026
A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
Challenges and opportunities for oncology drug repurposing informed by synthetic lethality
Michael Vermeulen1, Andrew W Craig2,3, Tomas Babak4,5
1Department of Biology, Queen's University, Kingston, ON, Canada. 0mcv@queensu.ca.
Abstract:
Although two-thirds of cancers arise from loss-of-function mutations in tumor suppressor genes, there are few approved targeted therapies linked to these alterations. Synthetic lethality offers a promising strategy to treat such cancers by targeting vulnerabilities unique to cancer cells with these mutations. To identify clinically relevant synthetic lethal interactions, we analyzed genome-wide CRISPR/Cas9 knock-out (KO) viability screens from the Cancer Dependency Map and evaluated their clinical relevance in patient tumors through mutual exclusivity, a pattern indicative of synthetic lethality. Indeed, we found significant enrichment of mutual exclusivity for interactions involving cancer driver genes compared to non-driver mutations. To identify therapeutic opportunities, we integrated drug sensitivity data to identify inhibitors that mimic the effects of CRISPR-mediated KO. This approach revealed potential drug repurposing opportunities, including BRD2 inhibitors for bladder cancers with ARID1A mutations and SIN3A-mutated cell lines showing sensitivity to nicotinamide phosphoribosyltransferase (NAMPT) inhibitors. However, we discovered that pharmacological inhibitors often fail to phenocopy KO of matched drug targets, with only a small fraction of drugs inducing similar effects. This discrepancy reveals fundamental differences between pharmacological and genetic perturbations, emphasizing the need for approaches that directly assess the interplay of loss-of-function mutations and drug activity in cancer models.
Insights
Synthetic lethality targets cancer vulnerabilities from tumor suppressor gene mutations. Researchers identified drug repurposing opportunities but found genetic and drug effects often differ, needing new assessment methods.
Area of Science:
- Oncology
- Genomics
- Pharmacology
Background:
- Two-thirds of cancers stem from tumor suppressor gene mutations, yet targeted therapies are scarce.
- Synthetic lethality offers a promising strategy to exploit cancer-specific vulnerabilities.
- Identifying reliable synthetic lethal interactions is crucial for developing new cancer treatments.
Purpose of the Study:
- To identify clinically relevant synthetic lethal interactions for targeted cancer therapy.
- To discover potential drug repurposing opportunities based on synthetic lethality.
- To evaluate the concordance between genetic perturbations and drug effects in cancer.
Main Methods:
- Analyzed genome-wide CRISPR/Cas9 knock-out (KO) viability screens from the Cancer Dependency Map.
- Evaluated clinical relevance of interactions using mutual exclusivity in patient tumors.
- Integrated drug sensitivity data to identify inhibitors mimicking genetic KO effects.
Main Results:
- Found significant mutual exclusivity enrichment for interactions involving cancer driver genes.
- Identified potential drug repurposing: BRD2 inhibitors for ARID1A-mutated bladder cancers and NAMPT inhibitors for SIN3A-mutated cells.
- Discovered that pharmacological inhibitors frequently fail to phenocopy genetic KO effects.
Conclusions:
- Synthetic lethality is a viable strategy for identifying cancer dependencies and therapeutic targets.
- Drug repurposing based on genetic screens shows promise but requires careful validation.
- Fundamental differences exist between genetic and pharmacological perturbations, necessitating novel approaches to assess drug efficacy in relation to specific mutations.
More Related Videos
14:51Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
Published on: June 17, 2022
08:46Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
Published on: December 9, 2015
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:26Drug Discovery: Overview
02:56Treatment Resistant Cancers
02:18Cancer